Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59244
Forster, M D; Dedes, K J; Sandhu, S; Frentzas, S; Kristeleit, R; Ashworth, A; Poole, C J; Weigelt, B; Kaye, S B; Rhoda Molife, L (2011). Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews. Clinical Oncology, 8(5):302-306.
PDF - Registered users only
On the basis of her sensitivity to repeated platinum treatment she was treated with the oral poly(ADP)-ribose polymerase (PARP) 1 inhibitor olaparib as part of a phase I trial. Repeat MRI scan at week 10 of treatment showed a significant reduction in the size of the brain metastases without steroid treatment or radiotherapy and the patient reported subjective improvement in tumor-related symptoms. After 8 months of olaparib treatment the patient developed objective disease progression. The tumor biopsy was negative for somatic BRCA1 and BRCA2 mutations, but displayed loss of PTEN, which has been suggested to be another predictive marker for sensitivity to PARP inhibitors. The patient remained alive for 10 months after completing olaparib, having gone on to derive further clinical benefit from repeat exposure to platinum-based therapy.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology|
|DDC:||610 Medicine & health|
|Deposited On:||17 Feb 2012 10:27|
|Last Modified:||27 Nov 2013 20:46|
|Publisher:||Nature Publishing Group|
|ISSN:||1759-4774 (P) 1759-4782 (E)|
|Citations:||Web of Science®. Times cited: 11|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page